ivabradine has been researched along with Heart Failure in 319 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (6.58) | 29.6817 |
| 2010's | 236 (73.98) | 24.3611 |
| 2020's | 62 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Malinowski, JT; St Jean, DJ | 1 |
| Bao, Q; Gong, M; Li, G; Li, Y; Shao, S; Suo, Y; Wang, X; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Farkas, AS; Hegyi, P; Nagy, N; Orosz, A; Polyák, A; Solymár, M; Soós, A; Tinusz, B; Tóth, N; Vágvölgyi, A; Váradi, A; Varró, A | 1 |
| Imamura, T; Kinugawa, K; Onoda, H; Uchida, K | 1 |
| Gluud, C; Jakobsen, JC; Liang, N; Maagaard, M; Nielsen, EE; Sethi, NJ; Yang, SH | 1 |
| Amano, T; Ando, H; Nakano, Y; Suzuki, W | 1 |
| Baopeng, T; Caizhen, Q; Huiyuan, H; Jingmin, Z; Junbo, G; Wenhui, D; Yamei, X; Yuhui, Z | 1 |
| Besser, S; Hori, M; Imamura, T; Kinugawa, K; Narang, N | 1 |
| Imamura, T; Kinugawa, K | 2 |
| Amrawy, AME; Dogheim, GM; El-Haggar, SM; Khairat, I; Omran, GA; Werida, RH | 1 |
| Aizawa, K; Hayasaka, T; Himuro, M; Ichikawa, T; Ishizawa, K; Ito, S; Nakamura, N; Suzuki, H; Toubai, T; Wanezaki, M; Watanabe, M; Yamada, A; Yamamoto, M; Yanagiya, R | 1 |
| Chang, JJ; Chen, MC; Jan, JY; Lin, MS; Lin, YS; Wang, PC; Yang, TY | 1 |
| Imamura, T; Izumida, T; Kinugawa, K | 1 |
| Chen, W; Fang, LG; Guo, XX; Lai, JZ; Li, JY; Lin, X; Liu, YX; Qian, H; Wu, W; Yang, J; Zhu, YL; Zhu, YY | 1 |
| Ishizawa, K; Toubai, T; Wanezaki, M; Watanabe, M; Yanagiya, R | 1 |
| Henmi, H; Imamura, T | 1 |
| Cui, D; Li, J; Liu, G; Liu, K; Lou, D; Lu, S; Ma, S; Pang, X; Wang, J; Wang, X; Wu, S; Xie, X; Xue, L; Yang, Z; Ye, F; Yu, H; Zhang, Y; Zhong, M | 1 |
| Bocchi, EA; Lima, IGCV | 1 |
| Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J | 1 |
| Evans, J; Lal, S; Sawant, S; Sindone, J; Wang, N | 1 |
| Arotsker, N; Besser, L; Bichovsky, Y; Fraenkel, M; Frenkel, A; Joshua, BZ; Klein, M; Zahger, D | 1 |
| Catagnano, F; Cavalotti, C; Malerba, G; Mazzetti, S; Morandi, F; Mortara, A; Nassiacos, D; Oliva, F; Rossi, J; Vecchio, C | 1 |
| Che Hassan, HH; Kamisah, Y | 1 |
| Agarwala, R; Kolapkar, V; Kumar, AS; Kumar, RVL; Mahala, BK; Mohan, JC; Panja, M; Patel, K; Ponde, CK; Sathyamurthy, I | 1 |
| Bekki, M; Chibana, H; Fukumoto, Y; Honda, A; Itaya, N; Nohara, S; Sato, H; Shibao, K; Shibata, R; Takahashi, J | 1 |
| Abdin, A; Batailler, C; Böhm, M; Borer, J; Ford, I; Komajda, M; Mahfoud, F; Slawik, J; Swedberg, K; Tavazzi, L | 1 |
| Joury, A | 1 |
| Çetin, T; Çınar, T; Çinier, G; Eren, S; Hayıroğlu, Mİ; Keskin, K; Pay, L; Tekkeşin, Aİ; Tezen, O; Yumurtaş, AÇ | 1 |
| Ako, J; Hagiwara, N; Inomata, T; Ito, H; Kawasaki, Y; Kihara, Y; Momomura, SI; Saito, Y; Sakata, Y; Shimokawa, H; Tanaka, T; Tsutsui, H; Yamamoto, K; Yamashina, A; Yano, M | 1 |
| Chen, S; Meng, Z; Peng, J; Sun, K; Wang, J; Wang, Q; Zhou, S; Zhou, Y | 1 |
| Atar, D; Marciniak, TA; Serebruany, V | 1 |
| Ohte, N; Seo, Y | 1 |
| Jorsal, A; McMurray, JJV; Nielsen, JC; Nielsen, RR; Pryds, K; Sommer, A; Wiggers, H | 1 |
| Bernier, V; Bohm, M; Borer, JS; Bouabdallaoui, N; Ford, I; Komajda, M; O'Meara, E; Swedberg, K; Tardif, JC; Tavazzi, L | 1 |
| Bonadei, I; Carubelli, V; Dallapellegrina, L; Sciatti, E; Vizzardi, E | 1 |
| Belenkov, YN; Ilgisonis, IS; Naymann, YI; Privalova, EA; Zhito, AV | 1 |
| Bosco-Lévy, P; Droz-Perroteau, C; Favary, C; Jové, J; Lassalle, R; Moore, N | 1 |
| Ajufo, E; Das, SR; Fonarow, GC; Navar, AM; Pandey, A; Sumarsono, A; Vaduganathan, M | 1 |
| Broe, M; Damkier, P; Ennis, ZN; Hallas, J; Hansen, MR; Hróbjartsson, A; Olesen, M; Pareek, M; Paulsen, NH; Pottegård, A; Videbæk, L | 1 |
| Bigelow, R; Cole, RT; DeVore, AD; Fonarow, GC; Ginwalla, M; Heitner, JF; Hernandez, AF; Lala, A; Lanfear, DD; Mentz, RJ; Old, W; Patel, CB; Piña, IL; Salacata, AS; Tasissa, G | 1 |
| DiDomenico, RJ; Griffin, T; Hellenbart, EL | 1 |
| Chokhandre, M; Dharod, D; Joshi, S; Khan, N; Mandrekar, A; Salvi, P | 1 |
| McMurray, JJV; Petrie, MC | 1 |
| Carvalho, VO; Conceição, LSR; Fernandes, RES; Gois, C; Júnior, MBG; Souza, DS | 1 |
| Iwahana, T; Kobayashi, Y; Okada, S | 1 |
| Ide, T; Kawasaki, Y; Tsutsui, H | 1 |
| Beak, YS; Choi, SH; Jang, JH; Kim, DH; Ko, KY; Kwan, J; Kwon, SW; Lee, MJ; Park, JH; Park, SD; Shin, SH; Woo, SI; Yoon, GS | 1 |
| Ahmed, MM; Al-Ani, M; Aranda, JM; Elzeneini, M; Parker, AM; Vilaro, JR | 1 |
| Hori, M; Imamura, T; Kinugawa, K; Nakamura, M | 1 |
| Adamcova, M; Aziriova, S; Baka, T; Krajcirovicova, K; Paulis, L; Repova, K; Simko, F | 1 |
| Benstoem, C; Brandenburg, V; Breuer, T; Heussen, N; Kalvelage, C; Marx, G; Stoppe, C | 1 |
| Babushkina, GV; Shaikhlislamova, GI | 1 |
| Hatani, Y; Hayashi, T; Hirata, KI; Imanishi, J; Tanaka, H; Yamauchi, Y | 1 |
| Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY | 2 |
| Kruszewski, M; Leszek, P; Mackiewicz, U; Mączewski, M; Oknińska, M; Paterek, A; Śmigielski, W; Sochanowicz, B | 1 |
| Abbas, M; Farooq, F; Imran, N | 1 |
| Banerjee, D; Wang, AY | 1 |
| Bryan Richard, S; Huang, B; Liu, G; Luo, S; Yang, Y | 1 |
| Imamura, T; Narang, N | 1 |
| Greco, S; Guadagnino, G; Mastroianni, A; Urso, F; Vangeli, V | 1 |
| Chang, HY; Chen, CH; Lan, WR; Lee, YH; Liao, FC; Lin, SI; Liu, PY; Tsai, CT; Wu, YJ | 1 |
| Ellis, MJ; Flannery, D; Jeklin, AT; La Gerche, A; Macefield, VG; Naughton, MT; Nilsen, K; Sully, F | 1 |
| Dolatshahi, Z; Mezginejad, F; Nargesi, S; Rashki Kemmak, A | 1 |
| Hori, M; Imamura, T; Kinugawa, K; Narang, N | 1 |
| Besser, S; Imamura, T; Kinugawa, K; Narang, N | 1 |
| Anguita, M; Hidalgo, FJ | 1 |
| Sargento, L | 1 |
| Grimm, D; Hedegaard, ER; Simonsen, U; Thorup, L | 1 |
| Adams, KF; Giblin, EM; Patterson, JH; Pearce, N | 1 |
| Stöckl, G; Störk, S; Zugck, C | 1 |
| Bisht, DS; Gokhroo, RK; Gupta, S; Kishore, K; Priti, K; Ranwa, BL | 1 |
| Bapat, A; Koplan, B; Mehta, N; Stevenson, WG; Tedrow, U | 1 |
| Azeem, S; Fernando, C; Moe, GW; Roth, S | 1 |
| Butler, J; Hamo, CE; Papadimitriou, L | 2 |
| Bekele, T; Hailu, A; Mengesha, HG; Otieno, MG; Petrucka, P; Weldearegawi, B | 1 |
| Böhm, M; Cohen-Solal, A; Dominjon, F; Henon-Goburdhun, C; Isnard, R; Komajda, M; Metra, M; Pannaux, M; Pieske, B; Ponikowski, P; Voors, AA | 1 |
| Granzier, H; Slater, RE; Strom, JG | 1 |
| Aydın, F; Bektur, S; Hüseyinoglu Aydın, A; Kıvrak, Y; Taşdelen, Y | 1 |
| Böhm, M; Borer, J; Cowie, M; Komajda, M; Lainscak, M; Nikolovska Vukadinović, A; Swedberg, K; Vukadinović, D | 1 |
| Butler, J; Papadimitriou, L | 1 |
| Bouvaist, H; Cosgrove, S; Ennezat, PV; Le Jemtel, TH; Marechaux, S; Vital Durand, D | 1 |
| Kiyakbaev, GK; Kobalava, ZD; Shavarov, AA | 1 |
| Clem, JR; Heins, J | 1 |
| Chien, FJ; Eisen, HJ; Kim, DH | 1 |
| Berger, F; Bonnet, D; Daubeney, PEF; Jokinen, E; Kantor, PF | 1 |
| Barach, PR; Lipshultz, SE; Wilkinson, JD | 1 |
| Eckman, PM | 1 |
| Bartholomew, RN; Sheridan, DJ | 1 |
| Kalra, PR; Kay, R; Rowell, N; Salek, MS; Sidorowicz, G; Spooner, C; Stevens, D; Taylor, J; Zachariah, D | 1 |
| Foley, PWX; Zivlas, C | 1 |
| Fejzic, D; Hoppe, UC; Jirak, P; Jung, C; Kretzschmar, D; Lichtenauer, M; Paar, V; Pistulli, R; Rohm, I; Schulze, PC; Wernly, B; Yilmaz, A | 1 |
| Musiałek, P | 2 |
| Brink, D | 1 |
| Adda, J; Akodad, M; Audurier, Y; Battistella, P; Belloc, C; Breuker, C; Castet-Nicolas, A; Chettouh, M; Cristol, JP; Curinier, C; Dupuy, AM; Fesler, P; Kalmanovich, E; Kuster, N; Lotierzo, M; Marques, S; Mercier, G; Roubille, C; Roubille, F; Solecki, K; Soltani, S; Verchere, A; Zerkowski, L | 1 |
| Chaanine, AH; Gladden, JD; Redfield, MM | 1 |
| Edelmann, F; Knosalla, C; Mörike, K; Muth, C; Prien, P; Störk, S | 1 |
| Banach, M; Bielecka-Dabrowa, A; Rysz, J; von Haehling, S | 1 |
| Abdullaev, TA; Berkinbaev, SF; Chesnikova, AI; Cowie, MR; Dadashova, GM; Glezer, MG; Grebennikova, AA; Hayrapetyan, HG; Kipiani, ZV; Koziolova, NA; Kurlyanskaya, AK; Lopatin, YM; Pagava, ZM; Rakisheva, AG; Sisakian, HS; Tarlovskaya, EI; Tseluyko, VI; Voronkov, LG | 1 |
| Bozkurt, B | 1 |
| Aspromonte, N; Grande, D; Iacoviello, M | 1 |
| El-Gowilly, SM; El-Naggar, AE; Sharabi, FM | 1 |
| Verrier, RL | 1 |
| Wu, A | 1 |
| Chow, SL; Depre, C; Page, RL | 1 |
| Kavtaradze, N; Saganelidze, K | 1 |
| Williams, MR | 1 |
| Bösch, C; Dobner, S; Hunziker, L; Martinelli, M; Rhyner, D; Schnegg, B; Suter, T; Wieser, M; Wigger, O | 1 |
| Alonso Salinas, GL; Castejón Navarro, B; Cuadrado Berrocal, I; Díez, J; Hernández Navarro, I; Largo Aramburu, C; Osorio Ruiz, Á; Pascual Izco, M; Ramírez-Carracedo, R; Sanmartín, M; Saura Redondo, M; Zamorano, JL; Zaragoza, C | 1 |
| Baena, CP; Bosch, NL; de Aragão Miguita, L; Hartmann, C; Tierie, E; Zytinski, L | 1 |
| Anguita, M; Castillo, JC; Hidalgo, F | 1 |
| Babayigit, E; Cavusoglu, Y; Mert, GÖ; Mert, KU | 1 |
| Andrey, JL; Aranda, R; Egido, J; Gomez, F; Gomez, R; Guzman, M; Pedrosa, MJ; Romero, SP | 1 |
| Dodd, K; Lampert, BC | 1 |
| Chan, CS; Chang, SL; Chen, SA; Chen, YC; Chen, YJ; Kao, YH; Lin, YK | 1 |
| Demacq, C; Gimpelewicz, CR; Gómez, EA; Martinez, F; McMurray, JJV; Packer, M; Ramires, FJA; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Bocchi, EA; Rassi, S; Veiga Guimarães, G | 1 |
| Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L | 1 |
| Borisenko, YV; Kanorskiy, SG | 1 |
| Maczewski, M | 1 |
| Canguven, O | 1 |
| Brugts, JJ; Brunner-La Rocca, HP; Hoes, AW; Linssen, GC; Rademaker, PC; Schaafsma, HJ; Smeele, FJ; van de Kamp, HJ; van Drimmelen, AA; Westendorp, PH | 1 |
| Gluud, C; Jakobsen, JC; Maagaard, M; Nielsen, EE | 1 |
| Agewall, S; Atar, D; Hall, TS; Marciniak, TA; Serebruany, VL | 1 |
| Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H | 1 |
| Asselbergs, FW; Bots, SH; Day, D; den Ruijter, HM; Eikendal, ALM; Groepenhoff, F; Miller, VM; Regitz-Zagrosek, V; Rochon, PA; Tannenbaum, C | 1 |
| Liu, CL; Xue, EZ; Zhang, MH | 1 |
| Bocchi, EA; Salemi, VMC | 1 |
| Acquistapace, F; Caminiti, G; Cice, G; D'Isa, S; Filardi, PP; Fini, M; Marazzi, G; Rosano, GMC; Vitale, C; Volterrani, M | 1 |
| Bauersachs, J; Berliner, D | 1 |
| Miao, W; Pei, H; Su, GH; Wang, W; Xie, WZ; Zhao, D; Zhao, Z | 1 |
| Amurthur, B; Anand, IS; Ardell, JL; DiCarlo, LA; Gregory, DD; KenKnight, BH; Libbus, I; Mittal, S; Monteiro, R; Premchand, RK; Sharma, K | 1 |
| Bobadilla, G; Bravo, C; Duarte, M; Guardamagna, C; Muñoz, P; Rossel, V; Verdugo, F | 1 |
| Baka, T; Simko, F | 1 |
| Lim, WY; Woldman, S | 1 |
| Böhm, M; Borer, JS; Ferrari, R; Ford, I; Fox, K; Komajda, M; Robertson, M; Steg, PG; Swedberg, K; Tavazzi, L; Tendera, M | 1 |
| Böhm, M; Reil, JC | 1 |
| Komajda, M | 3 |
| Chichkanov, GG; Tsorin, IB | 1 |
| Böhm, M; Borer, J; Ford, I; Komajda, M; Reil, JC; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Arai, Y; Igata, S; Kinoshita, H; Kuwabara, Y; Kuwahara, K; Minami, T; Nakagawa, Y; Nakao, K; Nishikimi, T; Shibata, J; Takano, M; Ueshima, K; Usami, S; Yamada, C; Yamada, Y; Yasuno, S | 1 |
| Hardman, SM | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Lainscak, M; Swedberg, K; Tavazzi, L | 1 |
| Akpek, M; Ates, I; Cetinkaya, R; Doğru, M; Genç, A; Kaya, MG; Keser, A; Sarıkaya, M; Ulucan, Ş; Yavuz, AH | 1 |
| Shah, SJ | 1 |
| Holland, DJ; Kosmala, W; Marwick, TH; Przewlocka-Kosmala, M; Rojek, A; Wright, L | 1 |
| Eriksson, U; Müller-Edenborn, B | 1 |
| Deedwania, P | 1 |
| Ferrari, R; Ford, I; Fox, K; Steg, PG; Tardif, JC; Tendera, M | 2 |
| Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G | 1 |
| Di Franco, A; Di Pasquale, P; Figliozzi, S; Lanza, GA; Parrinello, R; Salerno, Y; Sarullo, FM | 1 |
| Brunelli, C; Ferrero, S; Ghione, P; Rosa, GM; Valbusa, A | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Robertson, M; Swedberg, K; Tavazzi, L; van Veldhuisen, DJ; Voors, AA | 1 |
| Branscombe, N; Cowie, MR; Davies, A; Griffiths, A; Paracha, N; Sculpher, M | 1 |
| Bemelmans, RH; Visseren, FL | 1 |
| Hunter, R; Morris, S | 1 |
| Magni, L; Marabotti, C; Pellegrinetti, A; Testa, R; Venturini, E | 1 |
| Otto, CM | 1 |
| Cavusoglu, Y; Mert, U; Morrad, B; Mutlu, F; Nadir, A; Ulus, T | 1 |
| Caldarola, P; Carbonara, S; Cecere, A; Ciccone, MM; Cortese, F; Gesualdo, M; Iacoviello, M; Lagioia, R; Moncelli, M; Ricci, G; Riccioni, G; Scicchitano, P; Scrutinio, D; Zito, A | 1 |
| Bourke, JP; Keavney, BD; Koref, MS; Martin, RI; Pogoryelova, O; Teare, MD | 1 |
| Cowie, MR | 2 |
| Freye, R | 1 |
| Balta, S; Cuglan, B; Gozubuyuk, G; Kaplan, O; Karakus, Y; Kurtoglu, E; Yasar, E | 1 |
| Martinka, P; Stöckl, G; Zugck, C | 1 |
| Bogatyryov, Y; Christensen, LP; Dedkov, EI; McCooey, DS; Tomanek, RJ; Weiss, RM | 1 |
| Hampton, T | 1 |
| Lohmann, M | 1 |
| Maggioni, AP; Oliva, F; Polistena, B; Spandonaro, F | 1 |
| Beletsi, A; Branscombe, N; Karavidas, A; Kourlaba, G; Maniadakis, N; Milonas, C; Parissis, J | 1 |
| Baviera, EP; Di Franco, A; Lanza, GA; Mandalà, G; Marazia, S; Salerno, Y; Sarullo, FM; Sarullo, S; Vassallo, L; Vitale, G | 1 |
| Boyalla, V; Clark, AL; Cleland, JG; Dicken, B; Dierckx, R; Parsons, S; Pellicori, P; Putzu, P | 1 |
| Caetano, J; Delgado Alves, J | 1 |
| Aksan, G; Demirelli, S; Gulel, O; Icli, A; Inci, S; Nar, G; Soylu, K; Yuksel, S | 1 |
| Sayer, GT; Tannenbaum, S | 1 |
| Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M | 1 |
| Arkolaki, EG; Chlouverakis, GI; Kallergis, EM; Nakou, ES; Papakonstantinou, PE; Patrianakos, AP; Simantirakis, EN; Vardas, PE | 1 |
| Gvishiani, M; Isakadze, A; Makharadze, T | 1 |
| Traynor, K | 1 |
| Ashrafian, H; Dawson, DK; Dwight, JS; Francis, JM; Frenneaux, M; Mahmod, M; Neubauer, S; Pal, N; Rudd, A; Singh, S; Sivaswamy, N; Watkins, H; Yavari, A | 1 |
| Böhm, M; Borer, JS; Ford, I; Francq, BG; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Pereira-Barretto, AC | 1 |
| Chmelarova, A; Fedacko, J; Jackova, L; Janicko, M; Jedlickova, L; Majernik, J; Merkovska, L; Novakova, B; Pella, D | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Haddad, H; Yip, AM; Zhai, AB | 1 |
| Chaudhary, R; Freudenberger, R; Garg, J; Krishnamoorthy, P; Lanier, G; Martinez, MW; Shah, N | 1 |
| Ako, J; Hagiwara, N; Inomata, T; Ito, H; Kawasaki, Y; Kihara, Y; Momomura, S; Ogawa, H; Saito, Y; Shimokawa, H; Tanaka, T; Tsutsui, H; Yamashina, A | 1 |
| Al-Kindi, SG; Oliveira, GH; Orasanu, G | 1 |
| Hu, D; Sun, Y; Yu, J | 1 |
| Cammarano, C; Comee, M; Donovan, JL; Malloy, MJ; Silva, M | 1 |
| Böhm, M; Borer, J; Ewen, S; Ford, I; Komajda, M; Mahfoud, F; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Borer, JS; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Ewen, S; Ford, I; Komajda, M; Laufs, U; Lloyd, SM; Lopez-Sendon, J; Mahfoud, F; Ponikowski, P; Swedberg, K; Tavazzi, L | 1 |
| De Denus, S; Elzir, L; Henri, C; O'Meara, E; Tardif, JC | 1 |
| Enseleit, F; Flammer, AJ; Naegele, M; Ruschitzka, F | 1 |
| Korabathina, R; Wojnowich, K | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 2 |
| Fonarow, GC; Gordin, JS | 1 |
| Ayhan, S; Dönmez, İ; Erdem, A; Erdem, FH; Ozturk, S; Yazıcı, M | 1 |
| Heusch, G; Kleinbongard, P | 1 |
| Anker, SD; Cowie, MR; Filippatos, GS; Komajda, M; Mengelle, B; Ponikowski, P; Tavazzi, L | 1 |
| Al-Saadi, T; Al-Zakwani, I; Alshekaili, L; Sallam, M | 1 |
| Cowie, MR; Kansal, AR; Kielhorn, A; Krotneva, S; Tafazzoli, A; Yurgin, N; Zheng, Y | 1 |
| Anguita, M; Castillo, JC; Delgado, M; Durán, E; Ferreiro, C; Hidalgo, FJ; Mesa, D; Pan, M; Pardo, L; Rodríguez, S; Ruiz, M; Sánchez, JJ | 1 |
| Davis, K; Dietrich, E | 1 |
| Patel, S; Veltri, K | 1 |
| Bobadilla, RV; Foster, JL | 1 |
| Psotka, MA; Teerlink, JR | 1 |
| Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Martino, F; Pannarale, G; Pannitteri, G; Paravati, V; Tanzilli, G; Torromeo, C | 1 |
| Morales-Martínez de Tejada, Á | 1 |
| Barge-Caballero, E; Crespo-Leiro, MG; Grille-Cancela, Z; Hermida-Prieto, M; Marrón-Liñares, GM; Marzoa-Rivas, R; Muñiz-García, J; Núñez, L; Paniagua-Martín, MJ; Suarez-Fuentetaja, N; Vazquez-Rodriguez, JM | 1 |
| Hein, L; Lother, A | 1 |
| Hensey, M; O'Neill, J | 1 |
| Ayub-Ferreira, SM; Biselli, B; Bocchi, EA; Chizzola, P; Issa, VS; Lofrano-Alves, MS | 1 |
| Gong, TA; Hauptman, PJ; Vidic, A | 1 |
| Bertomeu-González, V; Bertomeu-Martínez, V; Bodí, V; Bosch, MJ; Chorro, FJ; Cordero, A; Fácila, L; Gallego, J; García-Blas, S; Llàcer, A; Llàcer, P; Mendizábal, A; Merlos, P; Miñana, G; Montagud, V; Morell, S; Núñez, J; Palau, P; Pedrosa, V; Sanchis, J; Santas, E | 1 |
| D'Ettorre, E; De Benedittis, G; de Gregorio, C; Della Rosa, G; Distante, A; Piscitelli, P | 1 |
| Rosenberg, K | 1 |
| Fayssoil, A | 1 |
| Khachatryan, A; Sargsyan, T; Sisakian, H | 1 |
| Hancox, JC; Melgari, D; Ng, GA | 1 |
| Alshammari, TM | 1 |
| Jennings, DL | 1 |
| Adhyaru, B; Raj, L | 1 |
| Böhm, M; Borer, JS; Ford, I; Kansal, AR; Kielhorn, A; Komajda, M; Krotneva, S; Maya, J; Patel, HK; Tafazzoli, A; Tavazzi, L | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Allen, CJ; Guha, K; Hartley, A; Sharma, R | 1 |
| Franz, M; Kretzschmar, D; Pistulli, R; Rohm, I; Schulze, PC; Stumpf, C; Yilmaz, A | 1 |
| Cao, X; Li, X; Sun, Z; Xia, H; Zhang, B | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Müller-Werdan, U; Stöckl, G; Werdan, K | 1 |
| Kanorskiy, SG; Pokrovskiy, VM; Tregubov, VG | 1 |
| Borisenko, YV; Kanorsky, SG | 1 |
| Cook, S; Delacrétaz, E; Hess, OM | 1 |
| Ferrari, R; Ford, I; Fox, K; Steg, PG; Tendera, M | 1 |
| van de Borne, P | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Cullington, D | 1 |
| Elder, D; Kalra, P; Lang, CC; Pauriah, M | 1 |
| Delcayre, C; Messaoudi, S; Milliez, P; Nehme, J; Rodriguez, C; Samuel, JL | 1 |
| Boos, C; Gorman, S | 1 |
| Goris, M; Henning, RH; Schoemaker, RG; Ulu, N; van Gilst, WH | 1 |
| D'Orazio, N; Riccioni, G; Vitulano, N | 1 |
| Böhm, M; Link, A; Reil, JC; Selejan, S | 1 |
| Abegunewardene, N; Münzel, T; Wenzel, P | 1 |
| Heusch, G | 2 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Reil, GH; Reil, JC | 1 |
| Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO | 1 |
| Bugatti, S; Dei Cas, L; Lombardi, C; Metra, M; Zacà, V | 1 |
| Arutiunov, AG; Arutiunov, GP; Volkova, AL | 1 |
| Akchurin, RS; Chernova, NA; Erastova, NV; Grishin, IR; Karpov, IuA; Latypov, RS; Lopukhova, VV; Mareev, IuV; Saidova, MA; Sapel'nikov, OV | 1 |
| Böhm, M; Borer, JS; Dubost-Brama, A; Ford, I; Komajda, M; Lerebours, G; Swedberg, K; Tavazzi, L | 2 |
| Hasenfuss, G | 1 |
| Thollon, C; Vilaine, JP | 1 |
| Di Pasquale, P; Fasullo, S; Fazio, G; Novo, S; Paterna, S; Puccio, D; Sarullo, FM | 1 |
| Ahmed, D; Clark, AL; Cleland, JG; Coletta, AP; Torabi, A | 1 |
| Bhargava, B; Parakh, N | 1 |
| Terracciano, CM; Yacoub, MH | 1 |
| Kosheleva, NA; Rebrov, AP | 1 |
| Hong, N; Kang, SM; Oh, J; Won, H | 1 |
| Gupta, A; Sharma, YP | 1 |
| Einecke, D | 1 |
| Rapezzi, C; Sinagra, G | 1 |
| Canet, E; Lerebours, G; Vilaine, JP | 1 |
| Ertl, G; Merx, MW | 1 |
| Hoppe, UC | 2 |
| Lopatin, IuM | 1 |
| Acquistapace, F; Caminiti, G; Cice, G; D'Isa, S; Fini, M; Marazzi, G; Perrone Filardi, P; Rosano, GM; Vitale, C; Volterrani, M | 1 |
| Fruhwald, F; Pieske, B | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; O'Meara, E; Swedberg, K; Tardif, JC; Tavazzi, L | 1 |
| Clark, AL; Cleland, JG; Cullington, D; Goode, KM | 1 |
| Kanorskiĭ, SG; Pokrovskiĭ, VM; Tregubov, VG | 1 |
| Albajrami, O; Bellumkonda, L; Jacoby, D | 1 |
| Brakenhielm, E; Debunne, M; Fang, Y; Henry, JP; Lallemand, F; Mulder, P; Richard, V; Thuillez, C; Vercauteren, M | 1 |
| Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Dei Cas, L; Del Magro, F; Piovanelli, B; Vizzardi, E | 1 |
| Ageev, FT | 1 |
| Heidenreich, PA; Kapoor, JR | 1 |
| Francis, GS; Sarraf, M | 1 |
| Castagno, D; Claggett, B; McMurray, J; Petrie, MC | 1 |
| Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C | 1 |
| Chilton, RJ; Lindsey, ML; Ma, Y | 1 |
| Aalbers, J | 2 |
| Böhm, M; Borer, J; Ford, I; Gonzalez-Juanatey, JR; Komajda, M; Lopez-Sendon, J; Reil, JC; Swedberg, K; Tavazzi, L | 1 |
| Anzai, T | 1 |
| Taylor, J | 1 |
| Bruhn, C | 1 |
| Böhm, M; Custodis, F; Fries, P; Fröhlig, G; Gräber, S; Granzier, HL; Hohl, M; Kazakov, A; Kratz, MT; Lenski, M; Müller, A; Neuberger, HR; Reil, GH; Reil, JC; Steendijk, P | 1 |
| Böhm, M; Borer, J; Ford, I; Komajda, M; Krum, H; Swedberg, K; Tase, A; Tavazzi, L | 1 |
| Guglin, M | 1 |
| Hall, AS; Schlosshan, D; Tan, LB | 1 |
| Brunetti, ND; Correale, M; Di Biase, M; Ieva, R; Montrone, D | 1 |
| Dias, P; Gandhi, A; Ibrahim, M; Navaratnarajah, M; Sarathchandra, P; Shah, A; Siedlecka, U; Terracciano, CM; van Doorn, C; Yacoub, MH | 1 |
| Dei Cas, L; Lupi, L; Manerba, A; Nodari, S; Triggiani, M | 1 |
| Deedwania, PC | 1 |
| Perry, CM | 1 |
| Alekseeva, IuM; Ardashev, AV; Fin'ko, VA; Potievskaia, VI; Sakovich, EA; Sitnikov, AV; Soiustova, EL | 1 |
| Barbier, S; Chagraoui, A; Henry, JP; Lallemand, F; Lerebours, G; Mahlberg-Gaudin, F; Mulder, P; Renet, S; Richard, V; Thuillez, C | 1 |
| Er, F; Hoppe, UC | 1 |
| Mulder, P; Thuillez, C | 1 |
| Bedossa, P; Ciobotaru, V; Escoubet, B; Heimburger, M; Heymes, C; Logeart, D; Louedec, L; Mercadier, JJ; Michel, JB; Ventura-Clapier, R | 1 |
| Tardif, JC | 1 |
| Mackiewicz, U; Maczewski, M | 1 |
| Agnesina, L; Bertoletti, A; Campana, C; De Ferrari, GM; Lettino, M; Mazzuero, A; Schwartz, PJ; Tavazzi, L | 1 |
102 review(s) available for ivabradine and Heart Failure
| Article | Year |
|---|---|
Next-generation small molecule therapies for heart failure: 2015 and beyond.
Topics: Heart Failure; Humans; Molecular Structure; Small Molecule Libraries | 2018 |
Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
Topics: Adult; Aged; Aged, 80 and over; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis.
Topics: Atrial Fibrillation; Bradycardia; Heart Failure; Humans; Ivabradine; Myocardial Infarction; Quality of Life | 2022 |
Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients.
Topics: Angiotensin Receptor Antagonists; Angiotensins; Female; Heart Failure; Humans; Ivabradine; Male; Sex Characteristics; Stroke Volume | 2023 |
Therapeutic Use and Molecular Aspects of Ivabradine in Cardiac Remodeling: A Review.
Topics: Animals; Benzazepines; Heart Failure; Heart Rate; Ivabradine; Quality of Life; Ventricular Remodeling | 2023 |
Pharmacology of Ivabradine and the Effect on Chronic Heart Failure.
Topics: Animals; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Ivabradine; Molecular Structure | 2019 |
Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Topics: Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Logistic Models; Randomized Controlled Trials as Topic | 2020 |
The role of heart rate and ivabradine in acute heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiovascular Agents; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Myocardial Contraction; Patient Discharge; Prognosis; Tachycardia | 2019 |
Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Cause of Death; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults.
Topics: Adult; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Sinoatrial Node | 2020 |
Use of Ivabradine in the Treatment of Tachyarrhythmias After Surgery for Congenital Heart Diseases.
Topics: Benzazepines; Heart Defects, Congenital; Heart Failure; Heart Rate; Humans; Ivabradine; Tachycardia | 2020 |
Effect of ivabradine on exercise capacity in individuals with heart failure with preserved ejection fraction.
Topics: Exercise Tolerance; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume | 2021 |
Hemodynamic effects of ivabradine use in combination with intravenous inotropic therapy in advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Stroke Volume | 2021 |
Ivabradine as adjuvant treatment for chronic heart failure.
Topics: Bias; Cardiovascular Agents; Cardiovascular Diseases; Chemotherapy, Adjuvant; Chronic Disease; Exercise Tolerance; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Stroke Volume | 2020 |
Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
Topics: Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Ventricular Function, Left | 2021 |
Effect of Reducing Heart Rate on Outcomes in Patients With Reduced Ejection Fraction.
Topics: Cardiovascular Agents; Digoxin; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume; Tachycardia | 2021 |
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review.
Topics: Chronic Disease; Cost-Benefit Analysis; Heart Failure; Humans; Ivabradine; Quality-Adjusted Life Years | 2022 |
Optimal Heart Rate Modulation Using Ivabradine.
Topics: Cardiac Output; Cardiovascular Agents; Echocardiography, Doppler; Heart Failure; Heart Rate; Humans; Ivabradine | 2021 |
Ivabradine: Current and Future Treatment of Heart Failure.
Topics: Benzazepines; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Heart; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators; Practice Guidelines as Topic; Stroke Volume | 2017 |
Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2017 |
Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.
Topics: Aged; Angina, Stable; Benzazepines; Cardiovascular Agents; Chi-Square Distribution; Coronary Artery Disease; Disease Progression; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Heart rate and its reduction in chronic heart failure and beyond.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Prognosis; Risk Factors | 2017 |
"Fast Track" Development and Approval Process for Heart Failure Therapeutics.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Discovery; Heart Failure; Humans; Ivabradine; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2017 |
Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction.
Topics: Angina Pectoris; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome | 2017 |
Pharmacologic Management for Heart Failure and Emerging Therapies.
Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan | 2017 |
Heart failure treatment: Keeping up with best practices.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Heart Failure with Preserved Ejection Fraction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Dyspnea; Exercise Tolerance; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Inflammation; Ivabradine; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Phosphodiesterase 4 Inhibitors; Risk Factors; Stroke Volume | 2018 |
Novel drugs for heart rate control in heart failure.
Topics: Cardiovascular Agents; Heart Failure; Heart Rate; Heart Ventricles; Humans; Ivabradine; Stroke Volume | 2018 |
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
Topics: American Heart Association; Angiotensin Receptor Antagonists; Biomarkers; Comorbidity; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; United States | 2018 |
The effects of heart rate control in chronic heart failure with reduced ejection fraction.
Topics: Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume | 2018 |
Heart Failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Cardiac Rehabilitation; Cardiovascular Agents; Coronary Artery Disease; Defibrillators, Implantable; Diabetes Complications; Diagnostic Techniques, Cardiovascular; Digoxin; Diuretics; Heart Failure; Hospitalization; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Palliative Care; Primary Prevention; Referral and Consultation; Risk Factors | 2018 |
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Treatment Outcome; Ventricular Dysfunction, Left | 2018 |
[MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Elapid Venoms; Heart; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, C-Type; Neoplasms; Survival Analysis; Trastuzumab; Trimetazidine; Troponin I | 2018 |
[Pharmacological therapy of heart failure with reduced ejection fraction].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Output, Low; Combined Modality Therapy; Diuretics; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan | 2018 |
The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Heart Failure; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2018 |
The Use and Indication of Ivabradine in Heart Failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine | 2018 |
[Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?]
Topics: Adrenergic beta-Antagonists; Aged; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2018 |
Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Mortality; Practice Guidelines as Topic; Research Design; Research Report; Sex Distribution; Sex Factors; Stroke Volume | 2019 |
Ivabradine for treatment of heart failure.
Topics: Animals; Cardiovascular Agents; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Humans; Ivabradine; Practice Guidelines as Topic; Stroke Volume; Ventricular Function, Left | 2019 |
New drugs: big changes in conservative heart failure therapy?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea | 2019 |
Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Topics: Cardiovascular Agents; Exercise Tolerance; Heart Failure; Humans; Ivabradine; Stroke Volume; Ventricular Function, Left | 2019 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Digoxin; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists | 2013 |
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Coronary Artery Disease; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
Heart rate and heart failure: the role of ivabradine therapy.
Topics: Anti-Arrhythmia Agents; Benzazepines; Depression, Chemical; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2013 |
[Management of heart failure: a challenge for healthcare systems].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Digitalis Glycosides; Disease Management; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Multicenter Studies as Topic; Stroke Volume; Vasodilator Agents | 2012 |
[Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
Topics: Adrenergic beta-Antagonists; Animals; Atherosclerosis; Benzazepines; Cardiotonic Agents; Heart; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Stroke Volume; Ventricular Dysfunction, Left | 2013 |
If current inhibition and mortality reduction in heart failure: more than just a 'pure' effect of lowering heart rate.
Topics: Benzazepines; Cardiotonic Agents; Heart Failure; Heart Rate; Humans; Ivabradine | 2013 |
[Heart failure - up to date].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Digoxin; Diuretics; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Hemodynamics; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Patient Readmission; Quality of Life; Survival Rate; Ventricular Dysfunction, Left | 2013 |
Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Heart Failure; Heart Rate; Humans; Ivabradine | 2013 |
Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Topics: Adrenergic beta-Antagonists; Benzazepines; Chronic Disease; Clinical Trials as Topic; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume | 2014 |
An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.
Topics: Animals; Benzazepines; Clinical Trials as Topic; Heart Failure; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2014 |
[The resting heart rate].
Topics: Benzazepines; Blood Pressure; Cardiovascular Diseases; Heart Failure; Heart Rate; Humans; Ivabradine; Prognosis; Risk Factors; Tachycardia | 2014 |
Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.
Topics: Animals; Benzazepines; Coronary Artery Disease; Heart Failure; Heart Rate; Humans; Ivabradine | 2014 |
Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials.
Topics: Angina Pectoris; Atrial Fibrillation; Benzazepines; Heart Failure; Humans; Incidence; Ivabradine; Randomized Controlled Trials as Topic; Risk Assessment | 2014 |
Heart rate and cardiovascular protection.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atherosclerosis; Benzazepines; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Heart Rate; Humans; Hypertension; Ivabradine; Myocardial Ischemia; Risk Factors | 2015 |
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Phosphodiesterase 5 Inhibitors; Renin-Angiotensin System; Spironolactone; Stroke Volume; Water-Electrolyte Imbalance | 2015 |
[The efficacy of ivabradine in chronic heart failure (review)].
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Heart; Heart Failure; Heart Rate; Humans; Ivabradine; Mice | 2015 |
Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Stroke Volume; Ventricular Remodeling | 2015 |
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Heart rate and heart failure.
Topics: Benzazepines; Cardiovascular Agents; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Outcome Assessment, Health Care; Ventricular Dysfunction, Left | 2016 |
Ivabradine: Heart Failure and Beyond.
Topics: Animals; Benzazepines; Cardiovascular Agents; Heart Conduction System; Heart Failure; Heart Rate; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Quality of Life; Recovery of Function; Treatment Outcome; Ventricular Function | 2016 |
Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
Topics: Adrenergic beta-Antagonists; Benzazepines; Coronary Artery Disease; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2016 |
Update on ivabradine for heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Quality of Life; Signal Transduction; Sinoatrial Node; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2016 |
Ivabradine for the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Chronic Disease; Exercise Tolerance; Heart Failure; Heart Rate; Humans; Ivabradine; Quality of Life; Treatment Outcome | 2016 |
Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Stroke Volume; Vasodilator Agents | 2016 |
Heart Failure Update: Outpatient Management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiotonic Agents; Cardiovascular Agents; Diet, Sodium-Restricted; Digoxin; Diuretics; Drug Combinations; Exercise Therapy; Fatty Acids, Omega-3; Female; Heart Failure; Heart Transplantation; Hospice Care; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan; Vasodilator Agents | 2016 |
New medications for heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Benzazepines; Biphenyl Compounds; Cyclic Nucleotide-Gated Cation Channels; Drug Combinations; Heart Failure; Heart Rate; Humans; Ivabradine; Neprilysin; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Signal Transduction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
Topics: Angina, Stable; Animals; Benzazepines; Cardiotonic Agents; Coronary Artery Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Longevity; Mice; Myocardial Ischemia; Myocardial Reperfusion; Swine | 2016 |
Ivabradine (Corlanor) for Heart Failure.
Topics: Atrial Fibrillation; Benzazepines; Bradycardia; Cardiovascular Agents; Drug Costs; Heart Failure; Humans; Hypertension; Ivabradine; Treatment Outcome | 2016 |
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Ivabradine: Role in the Chronic Heart Failure Armamentarium.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Ivabradine | 2016 |
Pharmacology of heart failure: From basic science to novel therapies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
Is Heart Rate a Norepiphenomenon in Heart Failure?
Topics: Adrenergic Antagonists; Amiodarone; Benzazepines; Depression, Chemical; Digoxin; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine | 2016 |
Ivabradine: Do the Benefits Outweigh the Risks?
Topics: Angina Pectoris; Benzazepines; Bradycardia; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Patient Safety; Recovery of Function; Risk Assessment; Risk Factors; Treatment Outcome; Ventricular Function, Left | 2017 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
Ivabradine.
Topics: Benzazepines; Cardiovascular Agents; Comorbidity; Diabetes Mellitus; Heart Failure; Hemodynamics; Hospitalization; Humans; Hypotension; Ivabradine; Pulmonary Disease, Chronic Obstructive; Quality of Life; Renal Insufficiency; Treatment Outcome | 2017 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
Ivabradine: A Current Overview.
Topics: Animals; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Ventricular Dysfunction, Left | 2016 |
Advances in the management of heart failure: the role of ivabradine.
Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Benzazepines; Biological Clocks; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Drug Therapy, Combination; Heart Conduction System; Heart Failure; Heart Rate; Humans; Ivabradine; Middle Aged; Patient Selection; Quality of Life; Risk Assessment; Risk Factors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2016 |
Heart failure guidelines: What's new?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
[What are the alternatives to betablockers in 2009?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Cardiomyopathies; Heart Failure; Heart Valve Diseases; Humans; Ivabradine; Myocardial Infarction; Myocardial Ischemia; Patient Selection; Stereoisomerism; Vasodilator Agents | 2008 |
Ivabradine: beyond heart rate control.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Heart Failure; Heart Rate; Heart Transplantation; Humans; Ivabradine; Nitrates; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2009 |
Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
Topics: Benzazepines; Cardiotonic Agents; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
[Heart rate: a risk factor or an epiphenomenon?].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Benzazepines; Calcium Channel Blockers; Cohort Studies; Cyclic Nucleotide-Gated Cation Channels; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hospitalization; Humans; Hypertension; Ivabradine; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Stereoisomerism; Tachycardia; Time Factors; Ventricular Dysfunction, Left | 2010 |
I(f) inhibition in cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Artery Disease; Cyclic Nucleotide-Gated Cation Channels; Dogs; Drugs, Investigational; Guinea Pigs; Heart Failure; Heart Rate; Humans; Ivabradine; Mice; Models, Animal; Rabbits; Sinoatrial Node | 2010 |
Heart rate and heart failure. Not a simple relationship.
Topics: Animals; Benzazepines; Cardiac Pacing, Artificial; Coronary Artery Disease; Disease Models, Animal; Heart Failure; Heart Rate; Humans; Ivabradine; Models, Cardiovascular; Multicenter Studies as Topic; Myocardial Ischemia; Myocardium; Randomized Controlled Trials as Topic; Stress, Mechanical; Tachycardia; Tachycardia, Supraventricular; Treatment Outcome; Ventricular Dysfunction, Left; Vertebrates | 2011 |
Rate control with ivabradine: angina pectoris and beyond.
Topics: Acute Coronary Syndrome; Angina Pectoris; Arrhythmias, Cardiac; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine | 2011 |
Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Topics: Animals; Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Models, Biological; Risk Assessment; Therapies, Investigational | 2011 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Cardiac Resynchronization Therapy; Combined Modality Therapy; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Survival Rate | 2011 |
[New therapeutic approaches in heart failure].
Topics: Adrenergic beta-Antagonists; Anemia, Iron-Deficiency; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynchronization Therapy; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Exercise Test; Heart Failure; Heart Rate; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic | 2011 |
[From results of BEAUTIFUL trial to results of SHIFT trial: BEAUTIFUL possibility to make a SHIFT in current guidelines].
Topics: Angina Pectoris; Benzazepines; Cardiovascular Agents; Cyclic Nucleotide-Gated Cation Channels; Disease Progression; Evidence-Based Medicine; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2011 |
The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Prognosis; Sinoatrial Node | 2011 |
Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Prognosis; Tachycardia | 2012 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; Carvedilol; Disease Progression; Heart Failure; Heart Ventricles; Humans; Ivabradine; Propanolamines; Sympathetic Nervous System; Ventricular Dysfunction, Left | 2012 |
[Ivabradine (pure heart-rate-lowering agent)].
Topics: Angina Pectoris; Animals; Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Mice | 2011 |
[Ivabradine: heart rate reduction in coronary heart disease and chronic heart failure].
Topics: Benzazepines; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Drug Interactions; Heart Failure; Heart Rate; Humans; Ivabradine | 2012 |
Heart rate reduction in heart failure: ivabradine or beta blockers?
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiotonic Agents; Europe; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Practice Guidelines as Topic; Treatment Outcome | 2013 |
Ivabradine for chronic heart failure?
Topics: Angina Pectoris; Benzazepines; Cardiotonic Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Topics: Adult; Animals; Benzazepines; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Heart rate slowing for myocardial dysfunction/heart failure.
Topics: Animals; Benzazepines; Cardiac Output; Cardiotonic Agents; Heart Conduction System; Heart Failure; Heart Rate; Humans; Ion Channels; Ivabradine; Myocardium; Rats; Sinoatrial Node | 2006 |
Clinical results of I(f) current inhibition by ivabradine.
Topics: Angina Pectoris; Benzazepines; Coronary Disease; Electrophysiology; Heart Failure; Heart Rate; Humans; Ion Channels; Ivabradine; Potassium; Sodium | 2007 |
51 trial(s) available for ivabradine and Heart Failure
| Article | Year |
|---|---|
Implication of Ivabradine Therapy in Up-Titrating Beta-Blocker Dose in Patients with Systolic Dysfunction.
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiovascular Agents; Echocardiography; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, Brain; Patient Readmission; Prospective Studies; Systole; Walk Test | 2021 |
Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients.
Topics: Anti-Arrhythmia Agents; Biomarkers; Chronic Disease; Diuretics; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, Brain; Neopterin; Stroke Volume | 2022 |
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
Topics: Benzazepines; Cardiovascular Agents; Delayed-Action Preparations; Double-Blind Method; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.
Topics: Aged; Cardiovascular Agents; Cause of Death; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Japan; Male; Middle Aged; Patient Admission; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Optimizing heart failure treatment following cardiac resynchronization therapy.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Topics: Aged; Cardiovascular Agents; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume | 2019 |
[The Use of Selective Inhibitor of If-Channels Ivabradine in Patients with Ischemic Heart Disease, Heart Failure with High Heart Rate].
Topics: Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Quality of Life | 2019 |
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiovascular Agents; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Discharge | 2020 |
Exercise oscillatory ventilation during autonomic blockade in young athletes and healthy controls.
Topics: Adult; Athletes; Breathing Exercises; Cardiovascular Agents; Case-Control Studies; Exercise; Exercise Test; Female; Heart Failure; Humans; Ivabradine; Male; Oxygen Consumption; Pulmonary Ventilation; Young Adult | 2021 |
Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine".
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Atrioventricular Block; Benzazepines; Cardiotonic Agents; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Heart Block; Heart Failure; Humans; Inferior Wall Myocardial Infarction; Ivabradine; Male; Metoprolol; Middle Aged; Prospective Studies; Recurrence; Survival Analysis | 2017 |
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Topics: Aged; Benzazepines; Cardiovascular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2017 |
Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Topics: Adolescent; Benzazepines; Cardiomyopathy, Dilated; Cardiovascular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Ivabradine; Male; Quality of Life; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2017 |
Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
Topics: Aged; Aged, 80 and over; Benzazepines; Cardiovascular Agents; Cohort Studies; Female; Follow-Up Studies; Heart Failure; Humans; Ivabradine; Male; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome; United Kingdom | 2017 |
Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Patient Care Planning; Patient Readmission; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan | 2018 |
Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Vagus Nerve Stimulation; Valsartan; Ventricular Function, Left; Walk Test | 2019 |
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.
Topics: Aged; Benzazepines; Bundle-Branch Block; Double-Blind Method; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Survival Rate; Treatment Outcome | 2013 |
Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
Topics: Aged; Benzazepines; Blood Flow Velocity; Cardiotonic Agents; Diastole; Double-Blind Method; Echocardiography, Doppler, Pulsed; Exercise Test; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Mitral Valve; Natriuretic Peptide, Brain; Oxygen Consumption; Prospective Studies; Ventricular Function, Left; Ventricular Pressure | 2013 |
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabra
Topics: Aged; Benzazepines; Coronary Artery Disease; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Morbidity; Radiography; Retrospective Studies; Stroke Volume; Survival Rate; Treatment Outcome; Ventricular Function, Left | 2013 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Propanolamines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2013 |
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Creatinine; Cyclic Nucleotide-Gated Cation Channels; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Humans; Ivabradine; Kidney; Kidney Diseases; Male; Middle Aged | 2014 |
Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Benzazepines; Cardiotonic Agents; Cardiovascular Agents; Dobutamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged | 2015 |
Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Ivabradine in stable coronary artery disease without clinical heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Diseases; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Risk | 2014 |
[Attaining therapy relevant goals with ivabradin].
Topics: Adrenergic beta-Antagonists; Benzazepines; Coronary Disease; Drug Therapy, Combination; Guideline Adherence; Heart Failure; Heart Rate; Humans; Ivabradine | 2014 |
Ivabradine on aortic stiffness in patients with heart failure.
Topics: Aged; Aorta; Benzazepines; Cardiovascular Agents; Female; Follow-Up Studies; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Ultrasonography; Vascular Stiffness | 2015 |
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Benzazepines; Biomarkers; Cross-Over Studies; Cyclic Nucleotide-Gated Cation Channels; Double-Blind Method; Endpoint Determination; Exercise Test; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Hypertension; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Sinoatrial Node; Stroke Volume; Treatment Failure | 2015 |
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Topics: Benzazepines; Cardiovascular Agents; Diabetes Complications; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Prognosis | 2015 |
Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
Topics: Aged; Angina, Stable; Benzazepines; Cardiovascular Agents; Drug Therapy, Combination; Endothelium, Vascular; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Male; Middle Aged; Sinoatrial Node | 2015 |
Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure - A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Topics: Aged; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged | 2016 |
[Status of β-blocker use and heart rate control in Chinese patients with stable coronary artery disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Outpatients; Percutaneous Coronary Intervention; Prospective Studies; Registries; Risk Factors | 2016 |
Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Topics: Aged; Benzazepines; Blood Pressure; Cardiovascular Agents; Double-Blind Method; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Office Visits; Predictive Value of Tests; Risk Assessment; Risk Factors; Systole; Time Factors; Treatment Outcome | 2016 |
Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Topics: Adrenergic Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Oman; Propanolamines; Prospective Studies; Quality of Life; Stroke Volume; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ventricular Function, Left | 2016 |
Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2016 |
Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study.
Topics: Acute Disease; Adult; Aged; Benzazepines; Cardiovascular Agents; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Risk Factors; Shock, Cardiogenic; ST Elevation Myocardial Infarction; Ventricular Function, Left | 2016 |
Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): A randomized, double-blind, placebo-controlled trial.
Topics: Benzazepines; Cardiovascular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Tachycardia, Sinus; Time Factors; Treatment Outcome | 2016 |
Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; CA-125 Antigen; Cardiac Pacing, Artificial; Cardiovascular Agents; Cause of Death; Defibrillators, Implantable; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Monitoring, Physiologic; Mortality; Myocardial Revascularization; Natriuretic Peptide, Brain; Patient Care Planning; Patient Readmission; Peptide Fragments; Sodium Potassium Chloride Symporter Inhibitors; Spain; Treatment Outcome | 2016 |
Effect of selective heart rate reduction through sinus node I
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Pulse Wave Analysis; Severity of Illness Index; Sinoatrial Node; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
[Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Benzazepines; Bisoprolol; Cardiovascular Agents; Exercise Tolerance; Female; Heart Failure; Heart Ventricles; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Quality of Life; Stroke Volume; Ventricular Function, Left | 2016 |
The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.
Topics: Aged; Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Ivabradine; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Ventricular Dysfunction, Left | 2008 |
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Protocols; Data Collection; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Ivabradine; Male | 2010 |
[Study evaluating the impact of a combination of inotropic support and heart rate control on prognosis and stabilization rate in patients with decompensated chronic heart failure (LEGION)].
Topics: Benzazepines; Blood Pressure; Cardiotonic Agents; Catheterization, Swan-Ganz; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Ivabradine; Male; Middle Aged; Monitoring, Physiologic; Myocardial Contraction; Pilot Projects; Prognosis; Prospective Studies; Pyridazines; Simendan; Treatment Outcome | 2010 |
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Severity of Illness Index; Sinoatrial Node; Treatment Outcome | 2010 |
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Severity of Illness Index; Sinoatrial Node; Treatment Outcome | 2010 |
Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.
Topics: Adrenergic beta-Antagonists; Benzazepines; Chronic Disease; Exercise; Exercise Test; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Neurotransmitter Agents; Off-Label Use; Oxygen Consumption; Quality of Life | 2010 |
[Dynamics of structural functional parameters of cardiovascular system in patients with Stable Angina and Congestive Heart Failure treated with Ivabradine for six months].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Benzazepines; Drug Therapy, Combination; Echocardiography; Electrocardiography, Ambulatory; Endothelium; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Treatment Outcome; von Willebrand Factor | 2010 |
Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Carvedilol; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Ivabradine; Male; Propanolamines; Prospective Studies; Quality of Life; Single-Blind Method; Treatment Outcome | 2011 |
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
[Alternative therapy with ivabradine in patients with functional class III chronic heart failure].
Topics: Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Agents; Chronic Disease; Drug Monitoring; Drug Therapy, Combination; Echocardiography; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Hypertension; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Severity of Illness Index; Treatment Outcome | 2011 |
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
Topics: Aged; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Topics: Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Treatment Outcome | 2013 |
Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
Topics: Adult; Benzazepines; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Ivabradine; Male; Middle Aged; Pilot Projects; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
166 other study(ies) available for ivabradine and Heart Failure
| Article | Year |
|---|---|
Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cells, Cultured; Diastole; Disease Models, Animal; Fibroblasts; Heart Failure; Heart Ventricles; Ivabradine; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Rats; Rats, Sprague-Dawley; Signal Transduction; Stroke Volume; Systole; Transfection; Treatment Outcome; Up-Regulation; Ventricular Dysfunction, Left | 2021 |
Effects of ivabradine on the prevention of intradialytic hypotension in a dialytic patient with heart failure with reduced ejection fraction.
Topics: Aged; Heart Failure; Humans; Hypotension; Ivabradine; Kidney Failure, Chronic; Male; Renal Dialysis; Stroke Volume | 2021 |
Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study.
Topics: Adult; Benzazepines; Cardiovascular Agents; China; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Prospective Studies; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2022 |
Prognostic Implications of Mitral Valve Inflow Pattern Overlap during Ivabradine Therapy.
Topics: Aged; Cardiovascular Agents; Coronary Circulation; Echocardiography; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Mitral Valve; Prognosis; Proportional Hazards Models; Retrospective Studies; Stroke Volume | 2022 |
Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure.
Topics: Aged; Echocardiography, Doppler; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Stroke Volume; Ventricular Function, Left | 2022 |
Ivabradine as an Adjuvant Agent for Severe Heart Failure Occurring in the Early Phase after Allogeneic Hematopoietic Cell Transplantation.
Topics: Cardiotoxicity; Graft vs Host Disease; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Ivabradine; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation.
Topics: Atrial Fibrillation; Cohort Studies; Heart Failure; Humans; Ivabradine; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Efficacy of Doppler echocardiography-guided ivabradine therapy.
Topics: Benzazepines; Cardiovascular Agents; Echocardiography, Doppler; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Ventricular Function, Left | 2023 |
Initiating ivabradine during hospitalization in patients with acute heart failure: A real-world experience in China.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2022 |
Response to: Implication of Ivabradine in Patients with Acute Heart Failure and Sinus Tachycardia Following Allogeneic Hematopoietic Cell Transplantation.
Topics: Heart Failure; Heart Rate; Hematopoietic Stem Cell Transplantation; Humans; Ivabradine; Tachycardia, Sinus | 2023 |
Implication of Ivabradine in Patients with Acute Heart Failure and Sinus Tachycardia Following Allogenic Hematopoietic Cell Transplantation.
Topics: Anti-Arrhythmia Agents; Benzazepines; Heart Failure; Heart Rate; Hematopoietic Stem Cell Transplantation; Humans; Ivabradine; Tachycardia, Sinus; Treatment Outcome | 2023 |
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2022 |
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2022 |
Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy - Case Report.
Topics: Adrenergic beta-Antagonists; Adult; Cardiomyopathies; Female; Heart Failure; Humans; Ivabradine; Tachycardia, Sinus; Thyrotoxicosis | 2023 |
Hemodynamic effects of heart rate lowering in patients admitted for acute heart failure: the RedRate-HF Study (Reduction of heart Rate in Heart Failure).
Topics: Aged; Aged, 80 and over; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Middle Aged; Prospective Studies; Stroke Volume | 2023 |
Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India.
Topics: Adrenergic beta-Antagonists; Consensus; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume; Syndrome; Ventricular Dysfunction, Left | 2023 |
Discontinuation of Intravenous Catecholamine by Oral Ivabradine in a Patient with Decompensated Heart Failure with Low Cardiac Output Syndrome.
Topics: Cardiac Output, Low; Catecholamines; Heart Failure; Heart Rate; Humans; Ivabradine | 2023 |
Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Topics: Benzazepines; Bradycardia; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2023 |
Optimizing heart rate with ivabradine in heart failure with reduced ejection fraction: Insights from a post-hoc analysis of the SHIFT trial.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2023 |
Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.
Topics: Arrhythmias, Cardiac; Heart Failure; Humans; Ivabradine; Retrospective Studies; Stroke Volume; Tachycardia, Ventricular; Ventricular Dysfunction, Left | 2023 |
Effects of Heart Rate Reduction by Ivabradine for Heart Failure Beyond β-Blockers.
Topics: Adrenergic beta-Antagonists; Heart Failure; Heart Rate; Humans; Ivabradine; Japan | 2019 |
Pharmacological treatment patterns in heart failure: a population-based cohort study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Clinical Protocols; Cohort Studies; Digoxin; Diuretics; Drug Substitution; Female; France; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Time Factors | 2020 |
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Drug Utilization; Heart Failure; Humans; Ivabradine; Medicaid; Medicare Part D; Tetrazoles; United States; Valsartan | 2020 |
Do We Need Clinical Events Committees to Adjudicate End Points?
Topics: Benzazepines; Heart Failure; Humans; Ivabradine | 2020 |
Is High Heart Rate Always Harmful to Heart Failure Patients?
Topics: Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Japan | 2020 |
Is High Heart Rate Always Harmful to Heart Failure Patients? - Reply.
Topics: Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Japan | 2020 |
Ivabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Drug Interactions; Electric Countershock; Electrocardiography; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Torsades de Pointes | 2020 |
Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure.
Topics: Adrenergic beta-Antagonists; Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Ventricular Dysfunction, Left | 2021 |
Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Heart Failure; Isoproterenol; Ivabradine; Male; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Function, Left; Ventricular Remodeling | 2021 |
[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].
Topics: Aged; Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Middle Aged; Prospective Studies; Quality of Life; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Effect of ivabradine on left ventricular diastolic function of patients with heart failure with preserved ejection fraction -IVA-PEF study.
Topics: Heart Failure; Humans; Ivabradine; Prospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Ivabradine prevents deleterious effects of dopamine therapy in heart failure: No role for HCN4 overexpression.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dopamine; Female; Heart Failure; Heart Rate; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Male; Muscle Proteins; Myocardium; Potassium Channels; Rats, Wistar; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Ivabradine effects on heart rate and quality of life among chronic heart failure patients.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Quality of Life; Treatment Outcome | 2021 |
Personalizing heart failure management in chronic kidney disease patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Glucose; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Receptors, Angiotensin; Renal Dialysis; Renal Insufficiency, Chronic; Sodium; Stroke Volume | 2022 |
Comment on: Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: Rationale and design of SHIFT-AHF trial.
Topics: Cardiovascular Agents; Heart Failure; Humans; Ivabradine | 2021 |
Efficacy of ivabradine in HIV-associated dilated cardiomyopathy.
Topics: Adult; Benzazepines; Cardiomyopathy, Dilated; Chronic Disease; Heart Failure; Heart Rate; HIV Infections; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2021 |
Implications of Doppler Echocardiography-guided Heart Rate Modulation Using Ivabradine.
Topics: Aged, 80 and over; Benzazepines; Echocardiography, Doppler; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Prospective Studies | 2021 |
Chronotropic Assessment in Patients with Constrictive Pericarditis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Pericarditis, Constrictive; Recurrence; Retrospective Studies | 2021 |
The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients.
Topics: Aged; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Ivabradine in acute decompensated systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine | 2017 |
Ivabradine in acute decompensated systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine | 2017 |
Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome | 2017 |
Inappropriate sinus tachycardia in a heart transplant successfully treated with ivabradine.
Topics: Action Potentials; Anti-Arrhythmia Agents; Benzazepines; Electrocardiography, Ambulatory; Electrophysiologic Techniques, Cardiac; Heart Failure; Heart Rate; Heart Transplantation; Humans; Ivabradine; Male; Middle Aged; Sinoatrial Node; Tachycardia, Sinus; Treatment Outcome; Ventricular Function, Left | 2017 |
Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Topics: Academic Medical Centers; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Benzazepines; Canada; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospitals, Community; Humans; Ivabradine; Male; Middle Aged; Risk Factors; Stroke Volume; Treatment Outcome | 2017 |
Effect of exercise on passive myocardial stiffness in mice with diastolic dysfunction.
Topics: Adaptation, Physiological; Animals; Benzazepines; Biomarkers; Cardiovascular Agents; Connectin; Diastole; Disease Models, Animal; Echocardiography; Gene Expression; Heart Failure; Heart Function Tests; Ivabradine; Male; Mice; Myocardial Contraction; Myocardium; Phosphorylation; Physical Conditioning, Animal | 2017 |
How does ivabradine effect erectile dysfunction in patients with heart failure?
Topics: Benzazepines; Cardiovascular Agents; Erectile Dysfunction; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Surveys and Questionnaires; Treatment Outcome | 2017 |
[A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina].
Topics: Angina, Stable; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Myocardial Ischemia; Sinoatrial Node | 2017 |
Evolving Pharmacologic Therapies for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2017 |
Does Lowering Heart Rate Improve Outcomes in Children With Dilated Cardiomyopathy and Chronic Heart Failure?
Topics: Benzazepines; Cardiomyopathy, Dilated; Child; Heart Failure; Heart Rate; Humans; Ivabradine | 2017 |
How Many Heart Failure Patients Might We SHIFT to a Lower Heart Rate?
Topics: Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume | 2017 |
What are luminous phenomena?
Topics: Benzazepines; Heart Failure; Humans; Ivabradine; Patient Education as Topic; Phosphenes | 2017 |
Ivabradine - well tolerated in elderly patients with systolic heart failure.
Topics: Aged; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2017 |
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Chronic Disease; Fatty Acid Binding Protein 3; Growth Differentiation Factor 15; Heart Failure; Humans; Ivabradine; Middle Aged; Receptors, Somatostatin; Receptors, Urokinase Plasminogen Activator; Young Adult | 2018 |
Drug action(s), drug marketing, and clinical medicine. Suppression of ventricular arrhythmogenicity with If blockade in human heart failure: emerging clinical evidence for ivabradine treatment benefit beyond heart rate control.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Marketing | 2017 |
Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Diuretics; Drug Combinations; Germany; Guidelines as Topic; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2018 |
Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Cardiovascular Agents; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Retrospective Studies | 2018 |
Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats.
Topics: Animals; Arterial Pressure; Autonomic Nervous System; Autonomic Nervous System Diseases; Baroreflex; Cardiotoxicity; Cardiovascular Agents; Cardiovascular System; Disease Models, Animal; Doxorubicin; Heart Failure; Heart Rate; Ivabradine; Male; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2018 |
Ivabradine's Pleiotropic Profile: Can It Protect Against Doxorubicin-Induced Heart Failure?
Topics: Benzazepines; Doxorubicin; Heart Failure; Humans; Ivabradine | 2018 |
The CARVIVA HF trial- Is the devil in the detail?
Topics: Carvedilol; Exercise; Heart Failure; Humans; Ivabradine | 2019 |
Ivabradine in acute heart failure: Effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial.
Topics: Acute Disease; Animals; Arterial Pressure; Cardiac Output; Cardiovascular Agents; Disease Models, Animal; Female; Heart Failure; Heart Rate; Ivabradine; Myocardial Infarction; Sus scrofa; Time Factors | 2020 |
Facts and details: Ivabradine in acute decompensated heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine | 2018 |
Facts and details: Ivabradine in acute decompensated heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine | 2018 |
Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Cardiovascular Agents; Cohort Studies; Comorbidity; Digoxin; Female; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Patient Readmission; Prognosis; Stroke Volume; Treatment Outcome | 2018 |
Heart Failure Differentially Modulates the Effects of Ivabradine on the Electrical Activity of the Sinoatrial Node and Pulmonary Veins.
Topics: Action Potentials; Animals; Cardiovascular Agents; Disease Models, Animal; Echocardiography; Electrocardiography, Ambulatory; Heart Failure; Heart Rate; Ivabradine; Male; Pulmonary Veins; Rabbits; Sinoatrial Node; Stroke Volume | 2018 |
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et
Topics: Chagas Cardiomyopathy; Chagas Disease; Heart; Heart Failure; Humans; Ivabradine | 2018 |
Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
Topics: Aminobutyrates; Biphenyl Compounds; Chagas Cardiomyopathy; Drug Combinations; Heart Failure; Humans; Ivabradine; Tetrazoles; Valsartan | 2018 |
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Cardiovascular Agents; Diastole; Dobutamine; Drug Therapy, Combination; Heart Failure; Ivabradine; Male; Myocardial Ischemia; Swine; Treatment Outcome; Urea | 2018 |
Does nitric oxide mediate the effects of ivabradine in patients with heart failure?
Topics: Benzazepines; Heart Failure; Humans; Ivabradine; Nitric Oxide | 2018 |
Effects of heart rate reduction with ivabradine on the international index of erectile function (IIEF-5) in patients with heart failure.
Topics: Erectile Dysfunction; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Penile Erection | 2020 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Cross-Sectional Studies; Female; Furosemide; Guideline Adherence; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Netherlands; Practice Guidelines as Topic; Registries; Renin-Angiotensin System; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Stroke Volume | 2019 |
Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.
Topics: Coronary Artery Disease; Heart Failure; Humans; Ivabradine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic | 2019 |
Ivabradine for heart failure: regulatory differences in Europe and United States.
Topics: Cardiovascular Agents; Drug Approval; Europe; Evidence-Based Medicine; Government Regulation; Healthcare Disparities; Heart Failure; Humans; Ivabradine; Patient Safety; Policy Making; Risk Assessment; Risk Factors; United States; United States Food and Drug Administration | 2019 |
Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiovascular Agents; Disease Models, Animal; Heart; Heart Failure; Heart Rate; Hypertension; Ivabradine; Male; Myocardium; Norepinephrine; Parasympathetic Nervous System; Rats, Inbred Dahl; Sodium Chloride, Dietary; Sympathetic Nervous System; Tyrosine 3-Monooxygenase; Ventricular Function, Left | 2019 |
Efficacy of ivabradine for heart failure: A protocol for a systematic review of randomized controlled trial.
Topics: Cardiovascular Agents; China; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic | 2019 |
Response letter to Dr. William's letter to the editor entitled "The CARVIVA HF trial - Is the devil in the detail?" published August 2018.
Topics: Carvedilol; Exercise; Exercise Tolerance; Heart Failure; Humans; Ivabradine | 2019 |
[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Tetrazoles; Valsartan | 2019 |
Ivabradine modulates the autonomic nervous system by affecting the "little brain" of the heart: A hypothesis.
Topics: Animals; Autonomic Nervous System; Autonomic Nervous System Diseases; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Models, Theoretical; Rats; Sinoatrial Node | 2019 |
Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts.
Topics: Animals; Arrhythmias, Cardiac; Benzazepines; Cations; Heart Failure; Heart Ventricles; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Mice; Mice, Transgenic | 2013 |
Ivabradine in heart failure: NICE guidance.
Topics: Benzazepines; Heart Failure; Heart Rate; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Practice Guidelines as Topic; Sinoatrial Node | 2014 |
Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
Topics: Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome | 2013 |
Effects of ivabradine on 6-minute walk test and quality of life in patients with previously implanted CRT-D.
Topics: Aged; Benzazepines; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Quality of Life; Retrospective Studies; Treatment Outcome | 2013 |
Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.
Topics: Benzazepines; Cardiotonic Agents; Exercise Tolerance; Female; Heart Failure; Humans; Ivabradine; Male | 2013 |
The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart Failure; Heart Rate; Hospital Costs; Humans; Ivabradine; Kaplan-Meier Estimate; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom | 2014 |
Ivabradine is cost-effective in the treatment of chronic heart failure.
Topics: Anti-Arrhythmia Agents; Benzazepines; Drug Costs; Heart Failure; Humans; Ivabradine; State Medicine | 2014 |
Myasthenia gravis and heart failure: is ivabradine a useful drug?
Topics: Aged, 80 and over; Benzazepines; Heart Failure; Humans; Ivabradine; Male; Myasthenia Gravis; Treatment Outcome | 2014 |
Exercise and the heart.
Topics: Anti-Arrhythmia Agents; Benzazepines; Biomedical Research; Cardiology; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug-Eluting Stents; Echocardiography, Doppler; Exercise; Heart Failure; Humans; Ivabradine; Life Style; Percutaneous Coronary Intervention; Predictive Value of Tests; Prognosis; Prosthesis Design; Risk Factors; Treatment Outcome | 2014 |
Ivabradine and atrial fibrillation: what should we tell our patients?
Topics: Angina Pectoris; Atrial Fibrillation; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Medication Therapy Management; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment | 2014 |
[Symptomatic coronary heart disease. Therapy with a beta blocker and ivabradine combination].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Coronary Disease; Drug Therapy, Combination; Guideline Adherence; Heart Failure; Humans; Ivabradine; Survival Rate | 2014 |
Progress in diagnosing and treating heart failure. New developments help keep patients out of hospital.
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; United States | 2014 |
[CHD and heart failure. Heart rate reduction guidelines as a therapy target].
Topics: Adrenergic beta-Antagonists; Benzazepines; Goals; Guidelines as Topic; Heart Failure; Heart Rate; Humans; Ivabradine | 2014 |
Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy.
Topics: Aged; Aged, 80 and over; Benzazepines; Cardiomyopathy, Dilated; Cardiotonic Agents; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2014 |
Effect of Chronic Heart Rate Reduction by I(f) Current Inhibitor Ivabradine on Left Ventricular Remodeling and Systolic Performance in Middle-Aged Rats With Postmyocardial Infarction Heart Failure.
Topics: Aging; Animals; Benzazepines; Collagen; Coronary Vessels; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Ivabradine; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Systole; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Clinical trial results may lead to changes in cardiovascular care.
Topics: Aminobutyrates; Angioplasty; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Myocardial Infarction; Practice Guidelines as Topic; Tetrazoles; Valsartan | 2014 |
[Cost-effectiveness and budget impact of ivabradine in heart failure therapy].
Topics: Benzazepines; Chronic Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heart Failure; Humans; Italy; Ivabradine; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years | 2014 |
Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Greece; Heart Failure; Humans; Ivabradine; Length of Stay; Markov Chains; Quality-Adjusted Life Years | 2014 |
Nemaline myopathy and heart failure: role of ivabradine; a case report.
Topics: Adult; Benzazepines; Cardiovascular Agents; Echocardiography; Electrocardiography; Heart Failure; Humans; Ivabradine; Male; Myopathies, Nemaline; Treatment Outcome | 2015 |
Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
Topics: Adrenergic beta-Antagonists; Aged; Appointments and Schedules; Benzazepines; Cardiovascular Agents; Cyclic Nucleotide-Gated Cation Channels; Drug Prescriptions; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Outpatients; Retrospective Studies; Time Factors; Ventricular Function, Left | 2015 |
Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Bisoprolol; Cardiovascular Agents; Chronic Disease; Clinical Protocols; Drug Utilization; Female; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Medication Therapy Management; Middle Aged; Retrospective Studies; United Kingdom | 2015 |
Long-term effect of If-channel inhibition on diastolic function and exercise capacity in heart failure patients with preserved ejection fraction.
Topics: Benzazepines; Diastole; Exercise Tolerance; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Time Factors | 2015 |
Ivabradine approved for stable chronic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Drug Approval; Heart Failure; Humans; Ivabradine; United States; United States Food and Drug Administration | 2015 |
Ivabradine (Corlanor) for heart failure.
Topics: Adult; Benzazepines; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Ivabradine; United States; United States Food and Drug Administration | 2015 |
Ivabradine in Management of Heart Failure: a Critical Appraisal.
Topics: Arrhythmias, Cardiac; Benzazepines; Cardiomyopathies; Cardiovascular Agents; Clinical Studies as Topic; Heart Failure; Heart Rate; Heart Transplantation; Humans; Ivabradine; Shock, Cardiogenic; Ultrasonography | 2016 |
Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Topics: Aged; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Female; Heart Failure; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Medication Adherence; Middle Aged; Mortality; Placebos; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2016 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asia; Australia; Benzazepines; Canada; Cardiovascular Agents; Chronic Disease; Europe; Female; Guideline Adherence; Heart Failure; Humans; Ivabradine; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Surveys and Questionnaires | 2016 |
Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
Topics: Aged; Benzazepines; Cardiovascular Agents; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Markov Chains; Medicare Part C; Middle Aged; Proportional Hazards Models; Quality-Adjusted Life Years; United States | 2016 |
Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
Topics: Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2016 |
About Bradycardia and Secondary Heart Failure Induced by Ivabradine in a Patient With HIV.
Topics: Benzazepines; Bradycardia; Cardiovascular Agents; Heart Failure; Heart Rate; HIV; HIV Infections; Humans; Ivabradine | 2016 |
About Bradycardia and Secondary Heart Failure Induced by Ivabradine in a Patient With HIV. Response.
Topics: Benzazepines; Bradycardia; Cardiovascular Agents; Heart Failure; Heart Rate; HIV; HIV Infections; Humans; Ivabradine | 2016 |
Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Cyclic Nucleotide-Gated Cation Channels; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; Heart Failure; Heart Rate; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Male; Middle Aged; Muscle Proteins; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Potassium Channels; RNA | 2016 |
Variations on a Precision Medicine Theme: One Size Fits Some.
Topics: Benzazepines; Cardiovascular Agents; Clinical Decision-Making; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; Humans; Ivabradine; Patient Selection; Precision Medicine; Prosthesis Design; Risk Factors; Treatment Outcome | 2016 |
Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: A chance for slowing progression of heart failure?
Topics: Adult; Benzazepines; Cardiomyopathy, Dilated; Cardiovascular Agents; Disease Progression; Heart Failure; Humans; Ivabradine; Male; Muscular Dystrophy, Duchenne; Treatment Outcome | 2016 |
New Recommendations for Heart Failure Treatment.
Topics: Antihypertensive Agents; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Valsartan | 2016 |
Which place for ivabradine in Duchenne muscular dystrophy with heart failure?
Topics: Benzazepines; Blood Gas Analysis; Cardiovascular Agents; Electrocardiography; Heart Failure; Humans; Ivabradine; Male; Muscular Dystrophy, Duchenne | 2016 |
Letter by Melgari et al Regarding Article, "Ivabradine: Role in the Chronic Heart Failure Armamentarium".
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2016 |
Heart Failure Therapy in 2016: SHIFTing the PARADIGM From Antiquated Therapies Toward Novel Agents.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Heart Failure; Humans; Ivabradine; Neprilysin; Practice Guidelines as Topic; Treatment Outcome | 2017 |
Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.
Topics: Benzazepines; Heart Failure; Heart Failure, Systolic; Hospitals; Humans; Ivabradine; Patient Readmission | 2017 |
Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzazepines; Biomarkers; Cardiovascular Agents; Chronic Disease; Comorbidity; Cytokines; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation Mediators; Ivabradine; Male; Middle Aged; Quality of Life; Risk Factors; Treatment Outcome | 2016 |
The Effects of Ivabradine on Cardiac Function after Myocardial Infarction are Weaker in Diabetic Rats.
Topics: Animals; Benzazepines; Cardiovascular Agents; Coronary Vessels; Diabetes Mellitus, Experimental; Disease Models, Animal; Echocardiography; Heart Failure; Heart Function Tests; Hyperglycemia; Ivabradine; Ligation; Male; Myocardial Infarction; Nerve Tissue Proteins; Norepinephrine; Rats; Rats, Sprague-Dawley; Signal Transduction; Streptozocin | 2016 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; Heart Failure; Humans; Hypertension; Ivabradine; Male; Metoprolol; Middle Aged; Quinapril; Random Allocation; Spironolactone; Tetrahydroisoquinolines; Treatment Outcome; Ventricular Function, Left | 2016 |
[Is resting heart rate a cardiovascular risk factor?].
Topics: Benzazepines; Cause of Death; Cyclic Nucleotide-Gated Cation Channels; Death, Sudden, Cardiac; Depression, Chemical; Heart Failure; Heart Rate; Humans; Ivabradine; Randomized Controlled Trials as Topic; Reference Values; Risk Factors | 2008 |
Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF.
Topics: Benzazepines; Biomarkers; Cardiology; Europe; Fatty Acids, Unsaturated; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Natriuretic Peptide, Brain; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Societies, Medical; Sulfonamides | 2008 |
Going for gold, from Beijing to Munich, highlights from the ESC 2008 Congress: BEAUTIFUL, GISSI-HF, and potential new therapies for acute decompensated heart failure.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiology; Drug Therapy, Combination; Fluorobenzenes; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Collagen; Disease Models, Animal; Drug Administration Schedule; Echocardiography, Doppler; Electrocardiography, Ambulatory; Fibrosis; Heart Failure; Heart Rate; Ivabradine; Male; Myocardial Infarction; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Severity of Illness Index; Stroke Volume; Telemetry; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2009 |
Ivabradine in heart failure: what about digoxin?
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiotonic Agents; Confounding Factors, Epidemiologic; Digoxin; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine | 2008 |
Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure.
Topics: Animals; Benzazepines; Heart Failure; Heart Rate; Ivabradine; Male; Metoprolol; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Dysfunction, Left | 2009 |
Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure.
Topics: Acute Disease; Benzazepines; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Tachycardia, Sinus; Treatment Outcome | 2009 |
Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Benzazepines; Cardiomyopathy, Restrictive; Cyclic Nucleotide-Gated Cation Channels; Echocardiography; Electrocardiography, Ambulatory; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Magnetic Resonance Imaging; Male; Myocardium; Treatment Outcome | 2009 |
A BEAUTIFUL lesson--ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Coronary Artery Disease; Heart Failure; Humans; Ivabradine; Myocardial Ischemia; Retrospective Studies; Ventricular Dysfunction, Left | 2009 |
[Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Benzazepines; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Hypoglycemic Agents; Ivabradine; Male; Metoprolol; Middle Aged; Treatment Outcome; Ventricular Function, Left | 2010 |
[Application of cardiac resynchronization therapy and ivabradine in a patient with chronic heart failure].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiovascular Agents; Digoxin; Diuretics; Echocardiography; Electrocardiography; Furosemide; Heart Atria; Heart Failure; Heart Rate; Heart Ventricles; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Spironolactone; Treatment Outcome | 2010 |
Benefit of heart rate reduction in heart failure.
Topics: Benzazepines; Cardiovascular Agents; Death, Sudden, Cardiac; Heart Failure; Heart Rate; Humans; Ivabradine; Life Expectancy; Randomized Controlled Trials as Topic | 2010 |
Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III.
Topics: Adrenergic beta-Antagonists; Benzazepines; Clinical Trials as Topic; Comorbidity; Cyclic Nucleotide-Gated Cation Channels; Drug Therapy, Combination; Erythropoietin; Heart Failure; Hematinics; Humans; Hyperkalemia; Ivabradine; Myocardial Infarction; Polymers; Renal Insufficiency; Stem Cell Transplantation | 2010 |
Heart failure: A SHIFT from ion channels to clinical practice.
Topics: Anti-Arrhythmia Agents; Benzazepines; Controlled Clinical Trials as Topic; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Hospitalization; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ivabradine; Potassium Channels; Treatment Outcome | 2010 |
Ivabradine and outcomes in chronic heart failure.
Topics: Benzazepines; Bundle-Branch Block; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Patient Selection; Randomized Controlled Trials as Topic; Sinoatrial Node; Treatment Outcome | 2010 |
Ivabradine and outcomes in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
[Heart failure. Heart rate control prevents clinical complications].
Topics: Benzazepines; Controlled Clinical Trials as Topic; Cyclic Nucleotide-Gated Cation Channels; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Ivabradine; Prognosis; Sinoatrial Node; Survival Rate | 2010 |
Heart rate decrease: a new paradigm in the treatment of heart failure. Insights from the SHIFT study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2011 |
[The SHIFT study].
Topics: Benzazepines; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic | 2011 |
Left ventricular remodelling in systolic heart failure using ivabradine. Slower is smaller is better?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Female; Heart Failure; Humans; Ivabradine; Male; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Limited role for ivabradine in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Benzazepines; Cardiotonic Agents; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Stroke Volume; Ventricular Dysfunction, Left | 2011 |
Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Heart Failure; Heart-Assist Devices; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Nitrates; Renin-Angiotensin System; Risk Factors; Survival Analysis; Sympathetic Nervous System; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
Topics: Animals; Benzazepines; Cell Hypoxia; Cell Proliferation; Diastole; Disease Models, Animal; Heart Failure; Heart Rate; Hypoxia-Inducible Factor 1, alpha Subunit; Ivabradine; Male; Myocardial Infarction; Nitric Oxide; Rats; Rats, Wistar; Time Factors; Vasodilation; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
[The SHIFT study: a shift in a correct direction].
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Protocols; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Practice Patterns, Physicians' | 2012 |
Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Digoxin; Female; Heart Failure; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Failure; Heart Rate; Immunohistochemistry; In Situ Nick-End Labeling; Ivabradine; Male; Metoprolol; Mice; Mice, Inbred C57BL; Multivariate Analysis; Random Allocation; Sensitivity and Specificity; Statistics, Nonparametric; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Heart rate reduction: an old and novel candidate heart failure therapy.
Topics: Animals; Benzazepines; Heart Failure; Ivabradine; Male; Metoprolol; Tachycardia; Ventricular Dysfunction, Left | 2012 |
From the AC congress, 24-27 March 2012.
Topics: Aged; Angina, Stable; Benzazepines; Diastole; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Mitral Valve Stenosis; Randomized Controlled Trials as Topic; Stroke Volume | 2012 |
The 2012 ESC Guidelines on Heart Failure.
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Eplerenone; Europe; Heart Failure; Humans; Infusions, Intravenous; Iron; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Societies, Medical; Spironolactone | 2012 |
Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.
Topics: Animals; Anti-Arrhythmia Agents; Aorta; Benzazepines; Blood Glucose; Collagen; Diastole; Heart Failure; Heart Rate; Hemodynamics; Insulin; Ivabradine; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred C57BL; Protein Kinases; RNA, Messenger; Stroke Volume; Systole; Vascular Stiffness; Ventricular Dysfunction, Left | 2013 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Care Team; Peptide Fragments; Spironolactone; Ventricular Dysfunction, Left | 2012 |
Cardiac functional benefits of ivabradine therapy in patients with severe heart failure.
Topics: Adult; Benzazepines; Heart Failure; Heart Function Tests; Humans; Ivabradine; Male; Middle Aged; Oxygen Consumption; Severity of Illness Index | 2013 |
Ivabradine in systemic sclerosis related pulmonary arterial hypertension.
Topics: Aged; Benzazepines; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Ivabradine; Middle Aged; Scleroderma, Systemic; Treatment Outcome | 2012 |
Influence of ivabradine on reverse remodelling during mechanical unloading.
Topics: Animals; Atrophy; Benzazepines; Calcium; Calcium Channels, L-Type; Excitation Contraction Coupling; Fibrosis; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; Ivabradine; Metoprolol; Myocardium; Rats; Ventricular Remodeling | 2013 |
[Chronic heart failure therapy: where we are and where we are going to].
Topics: Algorithms; Amides; Benzazepines; Chronic Disease; Fumarates; Heart Failure; Heart Rate; Humans; Ivabradine | 2012 |
Ivabradine reduces total hospital burden in heart failure.
Topics: Benzazepines; Disease Progression; Disease-Free Survival; Health Care Costs; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Length of Stay; Practice Guidelines as Topic | 2012 |
Ivabradine in heart failure: hope or hype?
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators | 2012 |
[The rare case of Bland-White-Garland syndrome in adult patient].
Topics: Adult; Benzazepines; Cardiovascular Agents; Cardiovascular Surgical Procedures; Coronary Angiography; Coronary Vessel Anomalies; Coronary Vessels; Female; Heart Failure; Humans; Ivabradine; Metoprolol; Mitral Valve Insufficiency; Multidetector Computed Tomography; Prognosis; Pulmonary Artery; Syndrome; Treatment Outcome | 2012 |
Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
Topics: Animals; Benzazepines; Capillaries; Cardiac Output; Collagen; Drug Evaluation, Preclinical; Heart Failure; Heart Rate; Heart Ventricles; Ion Transport; Ivabradine; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Sinoatrial Node; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling | 2004 |
[Ivabradine -- a novel approach for heart rate lowering].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Benzazepines; Contraindications; Electrocardiography; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Infarction; Randomized Controlled Trials as Topic; Sinoatrial Node; Treatment Outcome; Ventricular Function, Left | 2005 |
[Heart rate reduction as a therapeutic strategy: novel options].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Coronary Disease; Electrocardiography; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Contraction; Survival Rate | 2006 |
Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats.
Topics: Animals; Atrial Natriuretic Factor; Benzazepines; Heart Failure; Heart Rate; Hypertrophy, Left Ventricular; Ivabradine; Male; Rats; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Pressure; Ventricular Remodeling | 2008 |
Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Disease Models, Animal; Heart Failure; Heart Rate; Hypertrophy, Left Ventricular; Ivabradine; Male; Metoprolol; Myocardial Infarction; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Calcium Exchanger; Ventricular Remodeling | 2008 |